Clinical Trials
34 trialsEverolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Trial of PTK787/ZK 222584 Plus Paclitaxel
Dana-Farber Cancer Institute
PTK/ZK in Disseminated Malignant Melanoma
University Hospital Schleswig-Holstein
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
Novartis
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
Northwestern University
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Dana-Farber Cancer Institute
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
Novartis
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
Novartis
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
Alliance for Clinical Trials in Oncology
PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
Alliance for Clinical Trials in Oncology
PTK/RAD
Duke University
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
Hoosier Cancer Research Network
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Duke University
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer
University of Michigan Rogel Cancer Center
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.
Bayer
PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
Duke University
PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma
Washington University School of Medicine
Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
Stanford University
Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors
Indiana University
PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs
Massachusetts General Hospital
Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery
National Cancer Institute (NCI)
PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer
Washington University School of Medicine
Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer
University of California, San Francisco
Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
European Organisation for Research and Treatment of Cancer - EORTC
PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer Research Team
Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer
Nevada Cancer Institute
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
M.D. Anderson Cancer Center
PTK787
Louisiana State University Health Sciences Center in New Orleans
PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib
University of Helsinki
Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer
Novartis
PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies
SCRI Development Innovations, LLC
Protein Tyrosine Kinases (PTK) in Multiple Myeloma
Dana-Farber Cancer Institute